 Joel Marrs
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2022 | 373 | 1.590 |
Why?
| | Antihypertensive Agents | 5 | 2021 | 429 | 1.580 |
Why?
| | Hypertension | 7 | 2021 | 1056 | 1.480 |
Why?
| | Pharmacists | 8 | 2023 | 234 | 1.440 |
Why?
| | Aspirin | 3 | 2015 | 324 | 1.200 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2015 | 401 | 1.110 |
Why?
| | Education, Pharmacy | 6 | 2023 | 123 | 0.970 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2017 | 2096 | 0.900 |
Why?
| | Text Messaging | 2 | 2023 | 152 | 0.900 |
Why?
| | Atrial Fibrillation | 2 | 2019 | 322 | 0.880 |
Why?
| | Cardiovascular Diseases | 7 | 2022 | 1727 | 0.880 |
Why?
| | Anticoagulants | 2 | 2019 | 550 | 0.860 |
Why?
| | Stroke | 4 | 2019 | 1022 | 0.760 |
Why?
| | Thiophenes | 2 | 2015 | 108 | 0.750 |
Why?
| | Allylamine | 2 | 2012 | 7 | 0.730 |
Why?
| | Hypolipidemic Agents | 3 | 2011 | 86 | 0.720 |
Why?
| | Internship, Nonmedical | 2 | 2010 | 18 | 0.610 |
Why?
| | Medication Reconciliation | 1 | 2018 | 25 | 0.590 |
Why?
| | Dyslipidemias | 3 | 2019 | 154 | 0.530 |
Why?
| | Kidney Failure, Chronic | 2 | 2011 | 489 | 0.510 |
Why?
| | Cholesterol, LDL | 5 | 2019 | 307 | 0.500 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1395 | 0.490 |
Why?
| | Pharmaceutical Services | 2 | 2020 | 77 | 0.490 |
Why?
| | Heart Failure, Diastolic | 1 | 2015 | 20 | 0.480 |
Why?
| | Ticlopidine | 1 | 2015 | 55 | 0.470 |
Why?
| | Drug-Eluting Stents | 1 | 2015 | 62 | 0.470 |
Why?
| | Thromboembolism | 1 | 2015 | 92 | 0.470 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 1013 | 0.470 |
Why?
| | Medically Underserved Area | 1 | 2015 | 80 | 0.460 |
Why?
| | Blood Pressure | 3 | 2016 | 1538 | 0.430 |
Why?
| | Piperazines | 1 | 2015 | 309 | 0.410 |
Why?
| | Guideline Adherence | 1 | 2016 | 490 | 0.410 |
Why?
| | Patient Discharge | 2 | 2018 | 773 | 0.410 |
Why?
| | Urban Population | 1 | 2015 | 397 | 0.410 |
Why?
| | Humans | 43 | 2023 | 114699 | 0.390 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 231 | 0.390 |
Why?
| | Glucosides | 1 | 2012 | 36 | 0.390 |
Why?
| | Thrombosis | 1 | 2015 | 298 | 0.390 |
Why?
| | Anticholesteremic Agents | 2 | 2012 | 128 | 0.370 |
Why?
| | Spironolactone | 1 | 2010 | 28 | 0.360 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2010 | 38 | 0.350 |
Why?
| | Administration, Oral | 3 | 2019 | 728 | 0.330 |
Why?
| | Preceptorship | 1 | 2010 | 62 | 0.330 |
Why?
| | Professional Role | 3 | 2020 | 149 | 0.320 |
Why?
| | Students, Pharmacy | 1 | 2010 | 98 | 0.310 |
Why?
| | Medication Therapy Management | 2 | 2020 | 67 | 0.300 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 951 | 0.290 |
Why?
| | Schools, Pharmacy | 3 | 2021 | 48 | 0.290 |
Why?
| | Benzodiazepines | 1 | 2008 | 116 | 0.290 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 179 | 0.280 |
Why?
| | Hypnotics and Sedatives | 1 | 2008 | 134 | 0.280 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2021 | 76 | 0.280 |
Why?
| | Hospitalization | 2 | 2015 | 1752 | 0.280 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2007 | 44 | 0.270 |
Why?
| | Renal Dialysis | 1 | 2010 | 374 | 0.270 |
Why?
| | Family Practice | 2 | 2010 | 427 | 0.270 |
Why?
| | Insurance Coverage | 1 | 2008 | 200 | 0.270 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2008 | 119 | 0.270 |
Why?
| | Certification | 3 | 2013 | 89 | 0.270 |
Why?
| | Aged | 10 | 2023 | 19074 | 0.260 |
Why?
| | Heart Failure | 1 | 2018 | 1945 | 0.250 |
Why?
| | Poverty | 1 | 2008 | 442 | 0.240 |
Why?
| | Faculty | 2 | 2017 | 130 | 0.230 |
Why?
| | Ambulatory Care | 1 | 2007 | 478 | 0.220 |
Why?
| | Social Identification | 1 | 2023 | 51 | 0.210 |
Why?
| | Specialization | 3 | 2013 | 115 | 0.210 |
Why?
| | Middle Aged | 10 | 2023 | 26738 | 0.210 |
Why?
| | Reminder Systems | 1 | 2023 | 160 | 0.190 |
Why?
| | Pharmacy | 1 | 2021 | 28 | 0.190 |
Why?
| | Colesevelam Hydrochloride | 2 | 2012 | 7 | 0.180 |
Why?
| | Pharmacy Service, Hospital | 2 | 2013 | 83 | 0.180 |
Why?
| | Cell Phone | 1 | 2021 | 76 | 0.180 |
Why?
| | Cardiovascular Agents | 1 | 2021 | 126 | 0.170 |
Why?
| | Secondary Prevention | 3 | 2016 | 222 | 0.170 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 900 | 0.170 |
Why?
| | Female | 12 | 2021 | 59520 | 0.170 |
Why?
| | Retrospective Studies | 6 | 2021 | 12555 | 0.170 |
Why?
| | Brain Ischemia | 2 | 2013 | 299 | 0.160 |
Why?
| | Software | 1 | 2023 | 530 | 0.160 |
Why?
| | Age Factors | 2 | 2016 | 2894 | 0.150 |
Why?
| | Societies, Pharmaceutical | 3 | 2021 | 27 | 0.150 |
Why?
| | Colorado | 2 | 2023 | 4100 | 0.150 |
Why?
| | Blood Glucose | 3 | 2012 | 1828 | 0.150 |
Why?
| | Heart Valve Diseases | 1 | 2019 | 161 | 0.140 |
Why?
| | Male | 10 | 2020 | 55606 | 0.140 |
Why?
| | Risk Factors | 5 | 2019 | 8632 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 932 | 0.140 |
Why?
| | 4-Hydroxycoumarins | 1 | 2016 | 4 | 0.140 |
Why?
| | Dissociative Disorders | 1 | 2016 | 21 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6347 | 0.130 |
Why?
| | Community Participation | 1 | 2017 | 116 | 0.130 |
Why?
| | Cholesterol | 3 | 2019 | 367 | 0.130 |
Why?
| | Vitamin K | 1 | 2016 | 42 | 0.130 |
Why?
| | Patient Transfer | 1 | 2018 | 143 | 0.130 |
Why?
| | Primary Prevention | 2 | 2014 | 172 | 0.130 |
Why?
| | Telemedicine | 1 | 2022 | 662 | 0.120 |
Why?
| | Adult | 7 | 2021 | 30553 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2016 | 243 | 0.120 |
Why?
| | Blood Coagulation Disorders | 1 | 2016 | 197 | 0.110 |
Why?
| | Treatment Outcome | 2 | 2019 | 9088 | 0.110 |
Why?
| | Diuretics | 2 | 2011 | 66 | 0.110 |
Why?
| | Suicide, Attempted | 1 | 2016 | 317 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4411 | 0.110 |
Why?
| | Medication Adherence | 2 | 2021 | 536 | 0.110 |
Why?
| | Emotional Intelligence | 2 | 2023 | 7 | 0.100 |
Why?
| | Acute Disease | 1 | 2015 | 911 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2015 | 341 | 0.100 |
Why?
| | United States | 7 | 2021 | 12186 | 0.100 |
Why?
| | Data Collection | 1 | 2014 | 620 | 0.100 |
Why?
| | Benzhydryl Compounds | 1 | 2012 | 60 | 0.100 |
Why?
| | Health Promotion | 1 | 2017 | 686 | 0.090 |
Why?
| | Hyperlipidemias | 1 | 2012 | 121 | 0.090 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4410 | 0.090 |
Why?
| | Sex Factors | 1 | 2016 | 1715 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 253 | 0.090 |
Why?
| | Universities | 1 | 2013 | 340 | 0.090 |
Why?
| | Drug Resistance | 1 | 2010 | 158 | 0.090 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 54 | 0.080 |
Why?
| | Pregnancy | 1 | 2021 | 5520 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2016 | 927 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2010 | 184 | 0.080 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 607 | 0.080 |
Why?
| | Advisory Committees | 2 | 2021 | 208 | 0.080 |
Why?
| | Patient-Centered Care | 1 | 2013 | 473 | 0.070 |
Why?
| | Emotions | 2 | 2023 | 472 | 0.070 |
Why?
| | Receptors, GABA-A | 1 | 2008 | 82 | 0.070 |
Why?
| | Exercise | 1 | 2017 | 1644 | 0.070 |
Why?
| | Dipeptidyl Peptidase 4 | 1 | 2007 | 11 | 0.070 |
Why?
| | Adamantane | 1 | 2007 | 16 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2015 | 1177 | 0.070 |
Why?
| | Young Adult | 4 | 2015 | 10471 | 0.070 |
Why?
| | Pyrrolidines | 1 | 2007 | 55 | 0.070 |
Why?
| | Eicosapentaenoic Acid | 1 | 2006 | 28 | 0.070 |
Why?
| | Hypertriglyceridemia | 1 | 2006 | 34 | 0.070 |
Why?
| | Nitriles | 1 | 2007 | 149 | 0.070 |
Why?
| | Aging | 1 | 2016 | 1618 | 0.070 |
Why?
| | Docosahexaenoic Acids | 1 | 2006 | 69 | 0.070 |
Why?
| | Insurance, Health | 1 | 2008 | 244 | 0.070 |
Why?
| | Risk Assessment | 2 | 2016 | 2968 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2009 | 292 | 0.060 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2006 | 122 | 0.060 |
Why?
| | Animals | 3 | 2012 | 31708 | 0.060 |
Why?
| | Triglycerides | 1 | 2006 | 467 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 525 | 0.060 |
Why?
| | Adolescent | 4 | 2015 | 17853 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 750 | 0.060 |
Why?
| | Pandemics | 2 | 2022 | 1320 | 0.060 |
Why?
| | Sleep | 1 | 2008 | 632 | 0.050 |
Why?
| | Curriculum | 1 | 2006 | 819 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 580 | 0.040 |
Why?
| | Students | 1 | 2023 | 502 | 0.040 |
Why?
| | Annual Reports as Topic | 1 | 2017 | 5 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 47 | 0.040 |
Why?
| | Organizational Policy | 1 | 2017 | 68 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1214 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 574 | 0.030 |
Why?
| | Eating | 1 | 2016 | 344 | 0.030 |
Why?
| | Clinical Competence | 2 | 2011 | 893 | 0.030 |
Why?
| | Mechanical Thrombolysis | 1 | 2013 | 5 | 0.030 |
Why?
| | Telephone | 1 | 2013 | 153 | 0.020 |
Why?
| | Thrombolytic Therapy | 1 | 2013 | 117 | 0.020 |
Why?
| | Adrenergic Antagonists | 1 | 2011 | 9 | 0.020 |
Why?
| | Renin | 1 | 2011 | 31 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 29 | 0.020 |
Why?
| | Phytotherapy | 1 | 2011 | 66 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 114 | 0.020 |
Why?
| | Drug Utilization | 1 | 2011 | 167 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 4895 | 0.020 |
Why?
| | Patient Care Management | 1 | 2010 | 53 | 0.020 |
Why?
| | Hospitals, University | 1 | 2010 | 172 | 0.020 |
Why?
| | Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 6220 | 0.020 |
Why?
| | Length of Stay | 1 | 2013 | 962 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1125 | 0.020 |
Why?
| | Patient Readmission | 1 | 2013 | 610 | 0.020 |
Why?
| | Prevalence | 1 | 2013 | 2251 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 380 | 0.020 |
Why?
| | Drug Combinations | 1 | 2006 | 287 | 0.020 |
Why?
| | Primary Health Care | 1 | 2015 | 1514 | 0.020 |
Why?
|
|
Marrs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|